183 related articles for article (PubMed ID: 37072398)
1. Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer.
Carter JM; Chumsri S; Hinerfeld DA; Ma Y; Wang X; Zahrieh D; Hillman DW; Tenner KS; Kachergus JM; Brauer HA; Warren SE; Henderson D; Shi J; Liu Y; Joensuu H; Lindman H; Leon-Ferre RA; Boughey JC; Liu MC; Ingle JN; Kalari KR; Couch FJ; Knutson KL; Goetz MP; Perez EA; Thompson EA
Nat Commun; 2023 Apr; 14(1):2215. PubMed ID: 37072398
[TBL] [Abstract][Full Text] [Related]
2. Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1-positive Triple-negative Breast Cancer.
Carter JM; Polley MC; Leon-Ferre RA; Sinnwell J; Thompson KJ; Wang X; Ma Y; Zahrieh D; Kachergus JM; Solanki M; Boughey JC; Liu MC; Ingle JN; Kalari KR; Couch FJ; Thompson EA; Goetz MP
Clin Cancer Res; 2021 Oct; 27(20):5628-5637. PubMed ID: 34108182
[TBL] [Abstract][Full Text] [Related]
3. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
4. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
5. Immunohistological analysis of B7-H4, IDO1, and PD-L1 expression and tumor immune microenvironment based on triple-negative breast cancer subtypes.
Sanuki F; Mikami Y; Nishimura H; Fujita Y; Monobe Y; Nomura T; Taira N; Moriya T
Breast Cancer; 2023 Nov; 30(6):1041-1053. PubMed ID: 37642903
[TBL] [Abstract][Full Text] [Related]
6. Effector memory cytotoxic CD3
Sun X; Zhai J; Sun B; Parra ER; Jiang M; Ma W; Wang J; Kang AM; Kannan K; Pandurengan R; Zhang S; Solis LM; Haymaker CL; Raso MG; Mendoza Perez J; Sahin AA; Wistuba II; Yam C; Litton JK; Yang F
Mod Pathol; 2022 May; 35(5):601-608. PubMed ID: 34839351
[TBL] [Abstract][Full Text] [Related]
7. A high CD8 to FOXP3 ratio in the tumor stroma and expression of PTEN in tumor cells are associated with improved survival in non-metastatic triple-negative breast carcinoma.
Tavares MC; Sampaio CD; Lima GE; Andrade VP; Gonçalves DG; Macedo MP; Cordeiro de Lima VC
BMC Cancer; 2021 Aug; 21(1):901. PubMed ID: 34362334
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
Li M; Li A; Zhou S; Xu Y; Xiao Y; Bi R; Yang W
BMC Cancer; 2018 Jan; 18(1):4. PubMed ID: 29291717
[TBL] [Abstract][Full Text] [Related]
9. Integrative prognostic analysis of tumor-infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy.
Yazaki S; Shimoi T; Yoshida M; Sumiyoshi-Okuma H; Arakaki M; Saito A; Kita S; Yamamoto K; Kojima Y; Nishikawa T; Tanioka M; Sudo K; Noguchi E; Murata T; Shiino S; Takayama S; Suto A; Ohe Y; Fujiwara Y; Yonemori K
Breast Cancer Res Treat; 2023 Jan; 197(2):287-297. PubMed ID: 36385236
[TBL] [Abstract][Full Text] [Related]
10. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
Zhang L; Wang XI; Ding J; Sun Q; Zhang S
Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
[TBL] [Abstract][Full Text] [Related]
11. An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers.
Bottai G; Raschioni C; Losurdo A; Di Tommaso L; Tinterri C; Torrisi R; Reis-Filho JS; Roncalli M; Sotiriou C; Santoro A; Mantovani A; Loi S; Santarpia L
Breast Cancer Res; 2016 Dec; 18(1):121. PubMed ID: 27912781
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.
Han M; Li J; Wu S; Wu C; Yu Y; Liu Y
Cancer Med; 2023 Feb; 12(3):2906-2917. PubMed ID: 36073303
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer.
Wang X; Liu Y
Pathol Res Pract; 2020 Mar; 216(3):152802. PubMed ID: 32005408
[TBL] [Abstract][Full Text] [Related]
14. Triple negative breast cancer - prognostic role of immune-related factors: a systematic review.
Stovgaard ES; Nielsen D; Hogdall E; Balslev E
Acta Oncol; 2018 Jan; 57(1):74-82. PubMed ID: 29168430
[TBL] [Abstract][Full Text] [Related]
15. Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study.
Sarradin V; Lusque A; Filleron T; Dalenc F; Franchet C
Breast Cancer Res; 2021 May; 23(1):61. PubMed ID: 34039396
[TBL] [Abstract][Full Text] [Related]
16. Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer.
Zhu X; Zhang Q; Wang D; Liu C; Han B; Yang JM
Cancer Biol Ther; 2019; 20(8):1105-1112. PubMed ID: 30929569
[No Abstract] [Full Text] [Related]
17. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
[TBL] [Abstract][Full Text] [Related]
18. Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer.
Qiu Y; Yang Y; Yang R; Liu C; Hsu JM; Jiang Z; Sun L; Wei Y; Li CW; Yu D; Zhang J; Hung MC
Oncogene; 2021 Aug; 40(31):4992-5001. PubMed ID: 34172932
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer.
Lee J; Kim DM; Lee A
Cancer Res Treat; 2019 Apr; 51(2):649-663. PubMed ID: 30064200
[TBL] [Abstract][Full Text] [Related]
20. Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC).
Blackley EF; Loi S
Breast; 2019 Nov; 48 Suppl 1():S44-S48. PubMed ID: 31839159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
